Global theranostics major Roche expands its digitalised medicine portfolio. The next agreed project is a digital diagnostics platform to improve oncology and critical care treatment.

Laboratoris Sanifit S.L., a clinical-stage biopharmaceutical company focused on treatments for calcification disorders, today announced the appointment of Cris Calsada as Chief Financial Officer.

Targovax ASA (OSE: TRVX) announces that Michael Bogenstaetter has been appointed as the Company’s Chief Business Officer (CBO). He will take up this role in January 2018.

A new method to test the likelihood of a drug turning into a potentially harmful version of itself when it enters the body has been developed by researchers at Cardiff University.

Japanese Pharma major Takeda had announced its intention to take over Belgian adipose stem cell therapy specialist Tigenix, which has already exclusively licenced its lead product darvadstrocel (Cx601) to treat Crohn’s disease. In December darvadstrocel received a recommendation from the European Medicines Agency to market the product in Europe  in patients with complex perianal fistulas, one of the most disabling manifestations of Crohn’s disease.

German human and veterinay medicines major Boehringer Ingelheim has more than doubled the amount in funding of its Venture Fund (BIVF) to €250m. Additionally, the investment focus has been extended to include infectious diseases and digital health.

Swiss allosteric modulation specialist Addex Therapeutics has licenced its GABA modulator ADX71441 to US addiction therapeutics expert Indivior plc.

Pharmapack 2018 Focus:?The dawning age of digital healthcare is expected to transform the pharma packaging and drug delivery sector. At the 21st edition of Pharmapack Europe (7-8 February, 2018, Paris), an expected 5000+ professionals and 400+ exhibiting companies – the industry’s largest meeting ever – will discuss the latest innovations in serialisation, connected devices, and digitalised meds. 

The UN Sustainable Development Goals (SDGs) provide a powerful blueprint for coordinating global efforts to end poverty through economic growth, reducing inequality, and providing better education, health, job opportunities, and environmental protection.

A triple receptor agonist developed for diabetes could be used to treat Alzheimer’s after scientists found it "significantly reversed memory loss" in mice through a triple mode of action.